1 in 5 primary care doctors currently administering COVID-19 vaccines: survey COVID-19 vaccine player AstraZeneca hands CEO $21.5M in pay for navigating pandemic Eyeing variants, Adagio starts phase 1 trial of COVID-19 antibody FDA leaders recount flaws in 2020's open-door policy for COVID-19 antibody tests Treating COVID-19 long-haulers with Amgen's sleeper heart drug Corlanor U.K. inspects AstraZeneca vaccine partner's India manufacturing, setting stage for supply boost New COVID-19 mutations putting a strain on trial resumptions: report CVS Health joins payer industry peers in posting declining gains from COVID-19 Healthcare roundup: COVID-19 vaccines being shipped to community health centers Biopharma roundup: AstraZeneca may tap Serum Institute for EU shots; Sanofi eyes 2021 mRNA vaccine launch Featured Story | By Heather Landi Primary care is at risk of being a largely untapped resource in the vaccine rollout, with 32% of doctors saying they have not been included in any state or regional distribution planning. read more |
| |
|---|
|
| | Webinar: Mapping the Pathway to Designing Successful Treatments Tuesday, February 23 | 11am ET / 8am PT Experts will introduce Catalent’s new integrated dose form design strategy based on an analyzation of your molecule, patient, and market. Learn how this solution delivers dose form recommendations that can help differentiate your product, improve customer acceptance, and turn your science into patient accepted and commercially successful medicines. Register Now. |
Top Stories By Angus Liu The decision to take AstraZeneca to the front line of developing pharmaceutical solutions against COVID-19 earned the British pharma global recognition—and CEO Pascal Soriot a big thank-you note in the form of a $21.5 million paycheck for 2020. read more By Nick Paul Taylor Adagio Therapeutics has dosed the first subject with its anti-SARS-CoV-2 antibody. Administration of the candidate, which Adagio expects to be effective against coronavirus variants, continues the rapid rise of the biotech helmed by Tillman Gerngross. read more By Conor Hale Over last March and April, the market was flooded with antibody tests for COVID-19, with many offering unverified claims of accuracy, while independent researchers found high rates of false results. read more By Arlene Weintraub A UCSD team found that in a small study, Amgen's heart failure drug Corlanor significantly relieved symptoms of postural orthostatic tachycardia syndrome, a disorder that causes a spike in heart rate, fatigue, weakness and other symptoms. The researchers suggested the drug could be useful in treating COVID-19 long-haulers. read more By Fraiser Kansteiner Britain's drug regulator is auditing Serum Institute of India's manufacturing processes, potentially teeing up imports of India-made AstraZeneca vaccines to the U.K. and Europe. The move comes as AstraZeneca hustles to boost EU shot supplies—and after the pharma giant last week suggested it could source doses from production facilities outside the region. read more By Ben Adams The new strains of COVID-19 that are more transmissible and potentially able to dampen vaccine efforts are causing clinical trial resumptions to slow. read more By Paige Minemyer CVS Health brought in $975 million in profit for the fourth quarter of 2020, a decline of 44% from the prior-year quarter. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Conor Hale AstraZeneca may call on Serum Institute of India to export shots to Europe. Plus, AZ chief Pascal Soriot earned $21.52 million last year, thanks in part to the company's COVID-19 work. Sanofi’s mRNA vaccine could launch this year. And a six-year-old heart failure drug from Amgen may help treat COVID "long-haulers." read more |
